Our Science

Hydronidone
MASH
Other Disease Areas

Latest news

Mar 12, 2026

Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Read more
Mar 02, 2026

Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline

Read more
Jan 05, 2026

Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting

Read more

More news

Back to Top
X